share_log

Hydreight Updates on VSDHOne: Revolutionizing Direct-to-Consumer Healthcare Across All 50 States

Hydreight Updates on VSDHOne: Revolutionizing Direct-to-Consumer Healthcare Across All 50 States

Hydreight關於VSDHOne的更新:在所有50個州徹底改變直接面向消費的醫療保健
GlobeNewswire ·  2024/12/16 20:00

VANCOUVER, British Columbia and LAS VEGAS, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight"or the "Company")(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is providing an update on VSDHOne, its Direct-to-Consumer (D2C) healthcare platform. Now fully operational in all 50 states, VSDHOne is redefining telehealth by offering businesses an unparalleled, end-to-end solution to launch their own healthcare brands—quickly, cost-effectively, and at scale.

溫哥華,不列顛哥倫比亞省和拉斯維加斯,2024年12月16日(環球新聞稿)-- Hydreight Technologies Inc. ("Hydreight"或 "公司")(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6),一個快速發展的移動臨床網絡和醫療平台,爲美國50個州提供靈活的家庭醫療服務,正在就VSDHOne,旗下的直接面向消費者(D2C)醫療平台進行更新。現在在所有50個州全面運營,VSDHOne通過爲企業提供無與倫比的端到端解決方案,重新定義遠程醫療,使其能夠迅速、經濟高效地推出自己的醫療品牌。

What is VSDHOne?

什麼是VSDHOne?

VSDHOne provides a comprehensive telemedicine platform that empowers businesses, including MedSpas, health and wellness entrepreneurs, retailers, and pharmaceutical brands, to create D2C healthcare solutions in days rather than months. The purpose of launching VSDHOne is to make it easy for any existing brick and mortar or individuals to launch a direct to consumer healthcare brand in a few weeks without worrying about compliance, doctor network, telemedicine and ecommerce Technology, Medical direction and oversight, Pharmacy network, and a medical legal framework in all 50 States.

VSDHOne提供一個全面的遠程醫療平台,賦能企業,包括醫療水療中心、健康和保健創業者、零售商以及藥品品牌,在幾天內而非幾個月內創建D2C醫療解決方案。推出VSDHOne的目的是讓任何現有的實體店或個人在幾周內輕鬆推出直接面向消費者的醫療品牌,而無需擔心合規性、醫生網絡、遠程醫療及電子商務科技、醫療方向和監督、藥房網絡,以及在所有50個州的醫療法律框架。

With the marriage of Virtual and at facility healthcare features, Companies can expand beyond their current Bricks and Mortar solutions.

通過虛擬和實體醫療功能的結合,公司可以超越現有的實體解決方案進行擴展。

Features include:

功能包括:

  • eCommerce Platform
  • Telemedicine Technology
  • Booking and Scheduling Technology
  • Nationwide Doctors Network in all 50 States
  • Pharmacy Network and fulfillment partners
  • Medical Direction
  • Medical Legal Structure
  • Payment Processing
  • LegitScript approved - Enterprise Partner
  • Affiliate Marketing Automation
  • 電子商務平台
  • 遠程醫療技術
  • 預定和調度科技
  • 覆蓋所有50州的全國醫生網絡
  • 藥品網絡和履約合作伙伴
  • 醫療指導
  • 醫療法律結構
  • 支付處理
  • LegitScript批准 - 企業合作伙伴
  • Affiliate營銷自動化

"VSDHOne bridges the gap in healthcare accessibility, empowering nontraditional players to deliver personalized, convenient care directly to consumers. This isn't just telemedicine; it's Telehealth 2.0," said Shane Madden, CEO, Hydreight Technologies.

"VSDHOne打破了醫療服務的可及性障礙,使非傳統參與者能夠直接向消費者提供個性化、便捷的護理。這不僅僅是遠程醫療;這就是Telehealth 2.0," Hydreight Technologies首席執行官Shane Madden說道。

Available Treatments on the platform:

平台上的可用治療方案:

There are currently about 40 products available on the platform for the clients to offer to their patients. VSDHOne supports a wide range of treatments tailored to meet growing consumer demand for convenient, personalized care. The platform currently offers:

目前平台上約有40種產品可供客戶提供給他們的病人。VSDHOne支持廣泛的治療方案,以滿足日益增長的消費對方便個性化護理的需求。該平台目前提供:

  • Skincare Treatments: Including acne and anti-aging solutions.
  • Hair Loss Treatments: Clinically-backed therapies to promote hair regrowth.
  • Sexual Health: Addressing common concerns with effective, discreet care.
  • Hormone Replacement Therapy: Including Sermorelin and Testosterone Replacement Therapy (TRT).
  • GLP-1 Weight Management: Cutting-edge treatments for obesity and weight management.
  • Peptides
  • 皮膚護理治療:包括痤瘡和抗衰老解決方案。
  • 脫髮治療:經過臨床驗證的療法以促進頭髮再生。
  • 性健康:針對常見問題提供有效、私密的護理。
  • 激素替代治療:包括Sermorelin和睾酮替代療法(TRT)。
  • GLP-1體重管理:針對肥胖和體重管理的最前沿治療。

Future Treatments Coming to the Platform

未來將有治療方案進入平台

Hydreight continues to expand VSDHOne's offerings to include innovative therapies:

Hydreight繼續擴展VSDHOne的服務,以包括創新療法:

  • Genetic Testing
  • Birth Control Options
  • Oral GLP-1 Therapies
  • NAD+ Nasal Spray for anti-aging and energy
  • Longevity-focused solutions
  • 基因檢測
  • 避孕期權
  • 口服GLP-1療法
  • NAD+鼻用噴霧用於抗衰老和能量提升
  • 專注於長壽的解決方案

These treatments position VSDHOne as a comprehensive solution for a wide array of consumer healthcare needs, creating opportunities for businesses to grow their offerings and drive recurring patient engagement.

這些治療使VSDHOne成爲滿足廣泛消費醫療需求的綜合解決方案,爲企業拓展產品提供了機會,並推動患者的重複參與。

Current Market and Its Gaps:

當前市場及其缺口:

Consumer trust in the healthcare system is at an all-time low. This is due to equal access to care and pricing. In certain states, there remains a significant limitation in accessing healthcare professionals. More than 80% of counties across the country lack access to services needed to maintain, much less improve, their health. That's approximately 30 million Americans who live in "healthcare deserts" where accessible physicians are scarce.

消費者信任 在醫療系統中的信任處於歷史最低水平。這是因爲護理和定價的平等獲取。在某些州,仍然存在獲取醫療專業人員的重大限制。 超過 全國各地缺乏維持健康所需的服務,更不用說改善健康了。大約有 3000萬 美國人生活在「醫療服務沙漠」中,那裏醫生資源稀缺。

Since the COVID-19 pandemic, the demand for telemedicine has surged, with adoption rates among physicians rising from 15.4% in 2019 to 86.5% in 2021. As telehealth continues to evolve, providers are expanding their services to include everything from live consultations to asynchronous treatments.

自新冠疫情以來,遠程醫療的需求激增,醫生的採用率從2019年的15.4%上升到2021年的86.5%。隨着遠程醫療的不斷髮展,提供者正在擴大他們的服務,包括從現場諮詢到異步治療的所有內容。

There are many online providers for these treatments but they either are using different providers for different needs or they may not follow the best practices to have the full compliance. VSDHOne empowers providers from online providers, health clubs to existing brick and mortar locations to expand their offerings to consumers directly without being worried about the medical operational side of the offerings. They place a widget on their website and as soon as a patient lands on their website, they will go through the VSDHOne widget step by step platform and will receive their treatments and medications.

這些治療有許多在線提供者,但他們要麼使用不同的提供者來滿足不同的需求,要麼可能沒有遵循最佳實踐以確保完全合規。VSDHOne使在線提供者、健康俱樂部和現有實體地點的提供者能夠直接向消費者擴展他們的產品,而無需擔心醫療運營方面的內容。他們在自己的網站上放置一個小部件,當患者訪問他們的網站時,將按照VSDHOne小部件的步驟逐步進行,並獲得治療和藥物。

A Compelling Business Model:

引人注目的商業模式:

VSDHOne operates on a SaaS-based model, with customers purchasing state-specific licenses and paying per-order fees for the platform's end-to-end capabilities. This provides Hydreight with a recurring revenue stream while offering clients unparalleled scalability.

VSDHOne 基於SaaS-雲計算模型運作,客戶購買特定州的許可證併爲平台的端到端能力支付按訂單費用。這爲Hydreight提供了一個經常性營業收入來源,同時爲客戶提供了無與倫比的可擴展性。

Since its soft launch in late Q2 2024, VSDHOne has been onboarding over 200 licenses, far exceeding expectations. The platform and management projects to have over 1,000 licenses by December 2025, creating significant recurring revenue opportunities.

自2024年第二季度末進行軟啓動以來,VSDHOne已成功接入超過200個許可證,遠超預期。該平台及管理層預計到2025年12月將擁有超過1,000個許可證,從而創造顯著的經常性營業收入機會。

VSDHOne team is projecting each license to process approximately between 5 to 20 orders per day after full onboarding. The company will aim to provide guidance to the market by the end of Q1 after fully onboarding the first group of licenses and monitoring their traction in the first months. Most of the orders and treatments are ongoing treatments that patients need to have follow up orders every month after the initial month.

VSDHOne團隊預計,經過全面接入後,每個許可證每天處理的訂單大約在5到20個之間。公司計劃在第一季度末向市場提供指導,屆時將完全接入第一批許可證並監測它們在初期幾個月的增長情況。大多數訂單和治療是患者需要在初始月份後每個月進行跟進的持續治療。

"Hims & Hers Health, Inc. reported that it processed approximately 2.66 million net orders with an Average Order Value ("AOV") of approximately $147 in the third quarter of 2024. This translates to an average of about 29,600 orders per day during that quarter. We are helping other vendors to have such infrastructure to offer similar services without being worried about the details of offering and operations" said Shane Madden, CEO, Hydreight Technologies.

"Hims & Hers Health, Inc. 報告稱,在2024年第三季度其處理了大約266萬筆淨訂單,平均訂單價值("AOV")約爲147美元。這相當於該季度每天約29,600筆訂單。我們正在幫助其他供應商擁有這樣的製造行業基礎設施,以便提供類似的服務,而不必擔心提供和運營的細節",Hydreight Technologies的首席執行官Shane Madden說道。

WEBINAR:

網絡研討會:

The Company's management, and Medical team will be hosting a webinar to discuss more details about this in January 2025.

公司的管理層和醫療團隊將於2025年1月舉辦網絡研討會,以討論更多相關細節。

For more information or to get started, please email business@vsdigitalhealth.com.

如需更多信息或開始,請發送電子郵件 business@vsdigitalhealth.com.

About VSDHOne - Direct to Consumer Platform
In a partnership with two other parties, Hydreight Technologies launched the VSDHOne (Read as VSDH-One)platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more.

關於VSDHOne - 直接面向消費者的平台
Hydreight Technologies與另外兩個合作方合作推出了VSDHOne(讀作VSDH-One)平台。VSDHOne簡化了公司和醫療水療業務進入合規在線醫療空間的挑戰。該平台將幫助所有業務在所有50個州內在幾天內推出直接面向消費者的醫療品牌。合規產品包括:GLP-1(賽美特肽,替爾塞肽),肽類,個性化醫療治療,瑟莫瑞林,睾酮替代療法("TRT"),脫髮,護膚,性健康等。

Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Hydreight投資了科技、法律和基礎設施來推出這個平台。VSDHOne平台爲希望推出直接面向消費者的醫療品牌的企業提供了完整的一站式解決方案。從合規和遠程醫療科技到全國性的醫生和藥房網絡,VSDHOne提供了進入在線醫療空間所需的所有工具。該平台旨在顯著減少啓動此類服務所涉及的時間和成本,使企業能夠在幾天內而非幾個月內上線。

About Hydreight Technologies Inc.

關於Hydreight科技公司。

Hydreight Technologies Inc. is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

Hydreight科技公司正在建立美國最大的移動診所網絡之一。其專有的全方位整合平台擁有超過2500名護士、100多名醫生以及覆蓋50個州的藥房網絡。該平台包括一套內置的易於使用的全方位工具,用於會計、文檔、銷售、庫存、預訂和管理患者數據,這使得獲得許可的醫療專業人員能夠直接爲患者在家、辦公室或酒店提供服務。Hydreight正在彌合提供者合規性與患者便利性之間的差距,賦能護士、醫療水療技術人員和其他獲得許可的醫療專業人員。Hydreight平台允許醫療專業人員獨立按照自己的條件提供服務,或將移動服務添加到現有的位置基礎運營中。Hydreight擁有一個5030億的藥房網絡,服務於所有50個州,並與美國認證的電子處方和遠程醫療提供者網絡密切相關。

On behalf of the Board of Directors

謹代表董事會

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

肖恩·馬登
董事長兼首席執行官:Jeremiah R. Young。
Hydreight科技有限公司

Contact
Email: ir@hydreight.com; Telephone: 1 (702) 970-8112

聯繫
電子郵件: ir@hydreight.com;電話:1 (702) 970-8112

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

本新聞稿不構成在美國銷售證券的要約。所提供的證券尚未,也不會根據1933年美國證券法(經修訂)進行註冊,因此在沒有美國註冊或適用的美國註冊要求豁免的情況下,不能在美國提供或出售這些證券。

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

TSXV及其監管服務提供商(如TSXV政策中定義的那樣)均不對本公告的充分性或準確性負責。本新聞稿不構成在美國出售證券的要約。所提供的證券未根據1933年修訂版的美國證券法進行註冊,也不會在未經美國註冊或適用豁免規定的情況下在美國境內提供或銷售。

Cautionary Note Regarding Forward-Looking Information

關於前瞻性信息的警示說明

This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "projecting", "expect" or similar expressions and includes information regarding expectations for the Company's growth, VSDHone's number of licenses and orders in 2025.

本新聞稿包含符合適用證券法定義的「前瞻性信息」的聲明,包括關於公司未來商業活動和運營表現的計劃、盈利能力的路徑、意圖、信念和當前預期的聲明。前瞻性信息通常通過「可能」、「將」、「可以」、「應該」、「會」、「打算」、「計劃」、「預期」、「相信」、「估計」、「預測」、「期待」或類似表達來識別,幷包括關於公司增長、VSDHone在2025年的許可證和訂單數量的預期信息。

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

投資者需謹慎,前瞻性信息並非基於歷史事實,而是反映公司管理層對未來結果或事件的預期、估計或預測,這些預期基於管理層在作出聲明時認爲合理的意見、假設和估計。儘管公司相信這些前瞻性信息中反映的預期是合理的,但此類信息涉及風險和不確定性,不應過分依賴,因爲未知或不可預測的因素可能對公司未來的結果、表現或成就產生重大不利影響。可能導致實際結果與前瞻性信息中預測結果顯著不同的關鍵因素包括:獲得公司運營的業務所需的監管和其他批准的能力,和/或公司股份在TSXV上市對關係的潛在影響,包括與監管機構、員工、供應商、客戶和競爭對手的關係;一般經濟、商業和政治狀況的變化,包括金融市場的變化;適用法律的變化;遵守廣泛的政府法規;以及作爲上市公司的管理時間的轉移。此前瞻性信息可能會受到公司業務和市場條件中的風險和不確定性的影響。

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

如果這些風險或不確定性中的一個或多個實現,或者支撐前瞻性信息的假設被證明不正確,實際結果可能與此處所描述的意圖、計劃、預期、相信、估計或期待的結果有重大差異。雖然公司已試圖識別可能導致實際結果與預期、估計或意圖有重大差異的重要風險、不確定性和因素,但可能還存在其他因素也會導致結果未能如預期、估計或意圖。除非適用法律另有要求,公司不打算並不承擔任何更新該前瞻性信息的義務。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論